BUSINESS COMBINATIONS (Details 10) (USD $)	12 Months Ended			1 Months Ended						1 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2010 Valeant Pharmaceuticals International ("Valeant")	Sep. 30, 2010 Valeant Pharmaceuticals International ("Valeant")	Sep. 28, 2010 Valeant Pharmaceuticals International ("Valeant")	Sep. 28, 2010 Valeant Pharmaceuticals International ("Valeant") Amounts Recognized as of Acquisition Date (as previously reported)	Dec. 31, 2011 Valeant Pharmaceuticals International ("Valeant") Measurement Period Adjustments	Dec. 31, 2011 Valeant Pharmaceuticals International ("Valeant") Amounts Recognized (as adjusted)	Sep. 30, 2010 Valeant Pharmaceuticals International ("Valeant") Pre merger	Dec. 31, 2010 Valeant Pharmaceuticals International ("Valeant") Post merger
Business Combinations
Right to receive converted common shares ratio					1.7809
Special dividend paid (in dollars per share)										$ 16.77	$ 1.00
Aggregate cash paid in payment of post-merger special dividend				$ 297,600,000
Shares issued in payment of post-merger special dividend				72,283
Fair Value of Consideration Transferred
Number of common shares of Biovail issued in exchange for Valeant common stock outstanding as of Merger Date					139,137,000
Value of share consideration (in dollars per share)						$ 26.35
Fair value of common shares issued			3,880,301,000		3,666,245,000
Number of common shares of Biovail expected to be issued pursuant to vested share-based based awards as a result of the Merger					1,694,000
Fair value of common shares to be issued pursuant to vested Valeant RSUs						44,643,000
Fair value of vested and partially vested Valeant stock options converted into Biovail stock options						110,687,000
Fair value of vested and partially vested Valeant RSUs converted into Biovail RSUs						58,726,000
Cash consideration paid and payable						51,739,000
Total fair value of consideration transferred						3,932,040,000	3,932,040,000		3,932,040,000
Weighted-average fair value of options converted (in dollars per share)					$ 17.63
Method and assumptions on valuation of stock options
Expected volatility (as a percent)					32.90%
Expected life					3 years 4 months 24 days
Risk-free interest rate (as a percent)					1.10%
Expected dividend yield (as a percent)					1.50%
Post-Merger compensation expense, stock options						17,200,000
Post-Merger compensation expense, time-based and performance-based RSUs						3,800,000
Income tax withholding paid by the Company	31,073,000	59,718,000	14,485,000		39,700,000
Aggregate cash paid in payment of pre-merger special dividend					13,700,000
Portion attributable to Mr. Pearson's pre-Merger service recognized in fair value of consideration transferred					12,100,000
Portion attributable to Mr. Pearson's post-Merger service recognized as share-based compensation expense					1,600,000
Assets acquired and liabilities assumed
Cash and cash equivalents							348,637,000		348,637,000
Accounts receivable							194,930,000		194,930,000
Inventories							208,874,000		208,874,000
Other current assets							30,869,000		30,869,000
Property, plant and equipment							184,757,000		184,757,000
Identifiable intangible assets, excluding acquired IPR&D							3,844,310,000	(224,939,000)	3,619,371,000
Acquired IPR&D	546,876,000	531,304,000					1,404,956,000	(4,195,000)	1,400,761,000
Other non-current assets							6,108,000		6,108,000
Current liabilities							(385,574,000)	874,000	(384,700,000)
Long-term debt, including current portion						(2,913,614,000)	(2,913,614,000)		(2,913,614,000)
Deferred income taxes, net							(1,467,791,000)	157,816,000	(1,309,975,000)
Other non-current liabilities							(149,307,000)	(46,022,000)	(195,329,000)
Total identifiable net assets							1,307,155,000	(116,466,000)	1,190,689,000
Equity component of convertible debt							(225,971,000)		(225,971,000)
Call option agreements							(28,000,000)		(28,000,000)
Goodwill							2,878,856,000	116,466,000	2,995,322,000
Total fair value of consideration transferred						$ 3,932,040,000	$ 3,932,040,000		$ 3,932,040,000